The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | The use of surrogate endpoints in CLL clinical trials
Florian Simon, MD, University Hospital Cologne, Cologne, Germany, summarizes his talk on ‘endpoint surrogacy in chronic lymphocytic leukemia (CLL)’ presented at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA. Although overall survival (OS) is considered the most clinically relevant endpoint in clinical trials, surrogate endpoints such as progression-free survival (PFS) and measurable residual disease (MRD) could be useful tools to expedite trial readout. The analysis of twelve trials from the German CLL Study Group found a strong correlation between these surrogate endpoints and OS, which held true for both targeted therapies and chemoimmunotherapy (CIT). This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
